EMBECTA CORP. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-01: Study NCT06692153; Company role Lead sponsor; Phase Not applicable; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-01 | NCT06692153 Embecta AID System in Adults With Type 2 Diabetes | Lead sponsor | Not applicable | Withdrawn | Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); Type 2 DM; T2DM With Inadequate Glycemic Control; T2DM (Type 2 Diabetes Mellitus); T2D; T2DM | 0 | 2026-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |